by and among P-NEWCOCommercialization Agreement • July 26th, 2006 • Patriot Scientific Corp • Communications equipment, nec • California
betweenCommercialization Agreement • March 12th, 2004 • Genta Inc De/ • Biological products, (no disgnostic substances) • New York
EX-10.17 4 a2220057zex-10_17.htm EX-10.17 COMMERCIALIZATION AGREEMENT by and between THERAVANCE, INC. and CLINIGEN GROUP PLC Dated: March 8, 2013 COMMERCIALIZATION AGREEMENTCommercialization Agreement • May 5th, 2020 • New York
This Commercialization Agreement (“Agreement”) dated March 8, 2013, is made by and between THERAVANCE, INC., a Delaware corporation having its principal office at 901 Gateway Boulevard, South San Francisco, California 94080, United States (“Theravance”), and CLINIGEN GROUP PLC, Pitcairn House Crown Square, Centrum 100, BURTON UPON TRENT, DE14 2WW United Kingdom (“Clinigen”). Theravance and Clinigen may be referred to as a “Party” or together, the “Parties”.
EXCLUSIVE LICENSE AND COLLABORATIVE RESEARCH, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and among ASTELLAS PHARMA INC. and ASTELLAS US LLC and AMBIT BIOSCIENCES CORPORATION December 18, 2009 CONFIDENTIALCommercialization Agreement • March 28th, 2013 • Ambit Biosciences Corp • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AND COLLABORATIVE RESEARCH, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made effective as of December 18, 2009, (the “Effective Date”), by and among ASTELLAS PHARMA INC., a Japanese corporation (“API”) and its indirect wholly owned subsidiary ASTELLAS US LLC, a Delaware limited liability company (“AUS”; collectively with API, “Astellas”), and AMBIT BIOSCIENCES CORPORATION, a Delaware corporation (“Ambit”).
SECOND AMENDMENT TO COMMERCIALIZATION AGREEMENTCommercialization Agreement • June 11th, 2021 • Sera Prognostics, Inc. • Services-medical laboratories
THIS Second Amendment to the January 9, 2017 Commercialization Agreement (“Second Amendment”), effective as of the date this Second Amendment is signed by both parties (the “Effective Date”), is made by and between Sera Prognostics, Inc. (“Sera”) and Laboratory Corporation of America Holdings (“Labcorp”). Sera and Labcorp may be referred to herein each as a “Party” or collectively as “Parties.”
AMENDMENT NO. 1 TO FEASIBILITY, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • June 22nd, 2010 • Auto Search Cars, Inc. • Pharmaceutical preparations • Delaware
This Amendment No. 1 to Feasibility, Development And Commercialization Agreement ("Amendment No. 1") is entered into effective January 23, 2007 (the "Amendment Date") by and between DURECT Corporation ("DURECT") and Voyager Pharmaceutical Corporation ("Voyager").
COMMERCIALIZATION AGREEMENTCommercialization Agreement • June 11th, 2021 • Sera Prognostics, Inc. • Services-medical laboratories • Delaware
This Commercialization Agreement (“Agreement”) is effective as of January 9, 2017 (“Effective Date”) and is entered into by and between Sera Prognostics, Inc. (“Sera”), a Delaware corporation with its principal place of business at 2749 East Parleys Way, Suite 200, Salt Lake City, Utah 84109, and Laboratory Corporation of America Holdings (“LabCorp”), a Delaware corporation with its principal place of business at 531 South Spring Street, Burlington, North Carolina 27215. Each of Sera and LabCorp is referred to herein as a “Party” and together as the “Parties.”
First Amendment to Commercialization AgreementCommercialization Agreement • June 11th, 2021 • Sera Prognostics, Inc. • Services-medical laboratories
This First Amendment to Commercialization Agreement (“Amendment”) is made and shall be effective upon the date this Amendment is signed by both Parties (“Amendment Date”) by and between Sera Prognostics, Inc. (“Sera”), a Delaware corporation with its principal place of business at 2749 East Parleys Way, Suite 200, Salt Lake City, Utah 84109, and Laboratory Corporation of America Holdings (“LabCorp”), a Delaware corporation with its principal place of business at 531 South Spring Street, Burlington, North Carolina 27215. Each of Sera and LabCorp is referred to herein as a “Party” and together as the “Parties.”
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIFTH AMENDMENT TO...Commercialization Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations
This FIFTH AMENDMENT TO COLLABORATIVE RESEARCH, LICENSE & COMMERCIALIZATION AGREEMENT (the “Fifth Amendment”) is effective from 15-December-2010 by and between:
EX-10.28 3 dex1028.htm CO-COMMERCIALIZATION AGREEMENT [*] indicates that a confidential portion of the text of this agreement has been omitted. The non- public information has been filed separately with the Securities and Exchange Commission....Commercialization Agreement • May 5th, 2020 • New York
This Co-Development and Co-Commercialization Agreement, dated as of December 17, 2003 (the “Effective Date”), is between XOMA (US) LLC, a Delaware limited liability company (“XOMA”), located at 2910 Seventh Street, Berkeley, CA 94710, and ALEXION PHARMACEUTICALS, INC., a Delaware corporation (“Alexion”), located at 352 Knotter Drive, Cheshire, CT 06410.
AMENDED AND RESTATED LICENSE & COMMERCIALIZATION AGREEMENT by and between LEE’S PHARMACEUTICAL holdings Limited, Zhaoke Pharmaceutical (HEFEI) Co. Ltd., lee’s pharmaceutical ( guangZhou ) limited AND PLX PHARMA llc AMENDED AND RESTATED LICENSE &...Commercialization Agreement • January 5th, 2016 • PLX Pharma Inc. • Pharmaceutical preparations • Hong Kong
This Amended and Restated License & Commercialization Agreement (“Agreement”) is entered into by and between PLx Pharma LLC, a Texas limited liability company having a principal place of business located at 8285 El Rio, Suite 130, Houston, Texas 77054 (“PLx”) and LEE’S PHARMACEUTICAL Holdings Limited (“Lee’s”), Zhaoke Pharmaceutical (HEFEI) Co. Ltd. (“Zhaoke”), and LEE’S PHARMACEUTICAL (GUANGzHOU ) LIMITED (“Guangzhou” ) (Guangzhou and, collectively, together with Lee’s and Zhaoke, “Licensee”). PLx and Licensee (and, respectively, Lee’s, Zhaoke and Guangzhou) may individually be referred to as Party or collectively as Parties.
EX-10.55 6 a2237754zex-10_55.htm EX-10.55 Execution Version COMMERCIALIZATION AGREEMENTCommercialization Agreement • May 5th, 2020 • Minnesota
This Commercialization Agreement (this “Agreement”) is made as of the date last signed by the Parties (the “Effective Date”), by and between United Therapeutics Corporation, a corporation incorporated under the laws of Delaware and having a place of business at 55 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709 (“UT”), and Medtronic, Inc., a corporation incorporated under the laws of the State of Minnesota and having its place of business at 8200 Coral Sea Street NE, Mounds View, Minnesota 55112 (“Medtronic”), each a “Party”, collectively the “Parties.”
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATIVE RESEARCH,...Commercialization Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH, LICENSE & COMMERCIALIZATION AGREEMENT (this “Agreement”) is effective from January 18, 2007 (the “Effective Date”) by and between:
CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...Commercialization Agreement • April 25th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
This License, Development and Commercialization Agreement shall become effective as of the 6th day of March, 2019 (the “Effective Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”), and Cellectis SA, a company incorporated under the laws of France having a principal place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a “Party” and collectively, as the “Parties.”
COMMERCIALIZATION AGREEMENTCommercialization Agreement • August 8th, 2014 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • California
This COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of August 22, 2011 (the “Effective Date”), by and between Depomed, Inc., a California corporation (“Depomed”), and Santarus, Inc., a Delaware corporation (“Santarus”). Each of Depomed and Santarus is referred to herein individually as a “party” and collectively as the “parties.”
BACKGROUNDCommercialization Agreement • December 7th, 2000 • Genvec Inc • Pharmaceutical preparations • California
AMENDED and RESTATED LICENSE, DEVELOPMENT & COMMERCIALIZATION AGREEMENT Between SCYNEXIS, Inc. And ELANCO ANIMAL HEALTH, a division of ELI LILLY AND COMPANYCommercialization Agreement • March 19th, 2014 • Scynexis Inc • Pharmaceutical preparations
This AMENDED and RESTATED LICENSE, DEVELOPMENT & COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and effective as of the last date of signature hereto (the “New Effective Date”) by and between:
EX-10.2 15 dex102.htm COMMERCIALIZATION AGREEMENT, BY AND BETWEEN THE COMPANY AND ICM, INC. *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 203.406 COMMERCIALIZATION AGREEMENTCommercialization Agreement • May 5th, 2020 • Colorado
This Commercialization Agreement (this “Agreement”) is effective as of October 16, 2008 (the “Effective Date”) by and between ICM, Inc., a Kansas corporation with its principal place of business at 310 N. First Street, Colwich, KS 67030 (“ICM”) and Gevo, Inc., a Delaware corporation with offices at 345 Inverness Drive South, Building C, Suite 310, Englewood, CO 80112 (“Gevo”) (Gevo and ICM are collectively referred to as the “Parties” and each individually as a “Party”). As used in this Agreement, the term “Affiliates” means and refers to any entity that controls, or is controlled by, or is under common control with, that entity.
COMMERCIALIZATION AGREEMENT by and among DEPOMED, INC., COLLEGIUM PHARMACEUTICAL, INC. and COLLEGIUM NF, LLC Dated as of December 4, 2017Commercialization Agreement • March 7th, 2018 • Collegium Pharmaceutical, Inc • Pharmaceutical preparations • New York
This Commercialization Agreement (this “Agreement”) is made as of December 4, 2017 (the “Effective Date”), by and among Depomed, Inc., a California corporation (“Depomed”), Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Collegium NF, LLC, a Delaware limited liability company and wholly owned subsidiary of Collegium (“Newco”). Each of Depomed, Collegium and Newco is referred to herein individually as a “party” and collectively as the “parties.”
EX-10.2 3 a09-30855_1ex10d2.htm EX-10.2 Development and Commercialization Agreement between ImmuPharma (France) S.A. as “ImmuPharma” and Anesta AG as “Anesta” relating to Lupuzor ** Portions of the Exhibit have been omitted and have been filed...Commercialization Agreement • May 5th, 2020
THIS DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement” is made as of the Effective Date as defined hereinafter and is made
AMENDED AND RESTATED COMMERCIALIZATION AGREEMENTCommercialization Agreement • August 3rd, 2012 • Gevo, Inc. • Industrial organic chemicals • Colorado
This Amended and Restated Commercialization Agreement (together with all appendices attached hereto, this “Agreement”) is made and entered into on this 11th day of August, 2011 (the “Commencement Date”), but effective as of October 16, 2008 (the “Effective Date”) by and between ICM, Inc., a Kansas corporation with its principal place of business at 310 N. First Street, Colwich, KS 67030 (“ICM”) and Gevo, Inc., a Delaware corporation with offices at 345 Inverness Drive South, Building C, Suite 310, Englewood, CO 80112 (“Gevo”) (Gevo and ICM are collectively referred to as the “Parties” and each individually as a “Party”). As used in this Agreement, the term “Affiliates” means and refers to any entity that controls, or is controlled by, or is under common control with, that entity.
AMENDMENT NO. 1 to PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) entered into and made effective as of the 22nd day of August, 2006 by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment effective date of September 30th, 2007 (the “Amendment Effective Date”). All capitalized terms not expressly defined in this Amendment shall have the meanings given to them in the Agreement.
AMENDED AND RESTATED COMMERCIALIZATION AGREEMENT Dated October 31, 2023Commercialization Agreement • March 28th, 2024 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Commercialization Agreement (this “Agreement”) is made as of October 31, 2023 (the “Execution Date”), by and between Atara Biotherapeutics, Inc., incorporated under the laws of Delaware and having its registered office at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA 91320 (“Atara”), and Pierre Fabre Medicament, having its registered office at les Cauquillous, 81500 Lavaur, France (“Partner”). Atara and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
COMMERCIALIZATION AGREEMENTCommercialization Agreement • February 17th, 2010 • Ecology Coatings, Inc. • Wholesale-industrial machinery & equipment • Wisconsin
This Commercialization Agreement (the “Agreement”) is entered into as of the 1st day of February, 2010 (the “Effective Date”), by and between WS Packaging Group, Inc., a Wisconsin corporation located at 2571 S. Hemlock Road, Green Bay, Wisconsin 54229 (“WSPG”), and Ecology Coatings, Inc., a Nevada corporation located at 2701 Cambridge Court, Suite 100, Auburn Hills, Michigan 48326 (“Ecology”).
AMENDMENT NO. 3 TO COMMERCIALIZATION AGREEMENTCommercialization Agreement • November 8th, 2018 • Assertio Therapeutics, Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 3 TO COMMERCIALIZATION AGREEMENT (this “Amendment No. 3”) is entered into as of November 8, 2018, by and among Assertio Therapeutics, Inc., a Delaware corporation (formerly known as Depomed, Inc., a California corporation) (“Depomed”), Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Collegium NF, LLC, a Delaware limited liability company and wholly owned subsidiary of Collegium (“Newco”) and amends that certain Commercialization Agreement, dated as of December 4, 2017, as amended by Amendment No. 1 dated as of January 9, 2018 and Amendment No. 2 dated as of August 29, 2018 (as amended, the “Commercialization Agreement”), by and among Depomed, Collegium, and Newco. Each of Depomed, Collegium and Newco is referred to herein individually as a “party” and collectively as the “parties.” Defined terms used herein but not otherwise defined herein shall have the meaning ascribed to such terms in the Commercialization Agreement.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COMMERCIALIZATION AGREEMENTCommercialization Agreement • January 2nd, 2014 • uniQure B.V. • Pharmaceutical preparations • England
This Commercialization Agreement (this “Agreement”) is entered into as of 29 April 2013 (the “Effective Date”), by and between uniQure Biopharma B.V., formerly known as Amsterdam Molecular Therapeutics (AMT) B.V., a Dutch corporation, with its offices at Meibergdreef 61, 1105 BA Amsterdam, The Netherlands (“uniQure”), and Chiesi Farmaceutici S.p.A., an Italian corporation, with its offices at Via Palermo, 26/A, 43122 Parma, Italy (“Chiesi”). uniQure and Chiesi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO COMMERCIALIZATION AGREEMENTCommercialization Agreement • March 7th, 2018 • Collegium Pharmaceutical, Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO COMMERCIALIZATION AGREEMENT (this “Amendment No. 1”) is entered into as of January 9, 2018, by and among Depomed, Inc., a California corporation (“Depomed”), Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Collegium NF, LLC, a Delaware limited liability company and wholly owned subsidiary of Collegium (“Newco”) and amends that certain Commercialization Agreement, dated as of December 4, 2017 (the “Commercialization Agreement”), by and among Depomed, Collegium, and Newco. Each of Depomed, Collegium and Newco is referred to herein individually as a “party” and collectively as the “parties.” Defined terms used herein but not otherwise defined herein shall have the meaning ascribed to such terms in the Commercialization Agreement.
COMMERCIALIZATION AGREEMENTCommercialization Agreement • February 24th, 2021 • Tandem Diabetes Care Inc • Surgical & medical instruments & apparatus • California
This Commercialization Agreement (this “Agreement”) is made and entered into on November 20, 2020 (the “Effective Date”) by and between Tandem Diabetes Care, Inc, having a principal place of business at 11075 Roselle St., San Diego, CA 92121 (“Tandem”) and DexCom, Inc., a Delaware corporation having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”). Tandem and DexCom may be referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL COMMERCIALIZATION AGREEMENT WITH RESPECT TO SISUNATOVIR BY...Commercialization Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations • New York
(1)LianBio Development (HK) Limited, a limited liability company organized under the laws of Hong Kong, having an address at RM 1901, 19/F Lee Garden One 33 Hysan Avenue, Causeway Bay HK (“LianBio Development”);
Patent and Know-How License, Development and Commercialization AgreementCommercialization Agreement • March 16th, 2006 • Avigen Inc \De • In vitro & in vivo diagnostic substances
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • July 29th, 2009 • Medarex Inc • Services-commercial physical & biological research • New York
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), dated as of April 20, 2009 (the “Execution Date”), is entered into by and between MERCK SHARP & DOHME RESEARCH LTD. with a principal place of business at Chesney House, 96 Pitts Bay Road, Pembroke HM 08, Bermuda (“Merck”), and MEDAREX, INC., 707 State Road, Princeton, NJ 08540, USA (“Medarex”), UNIVERSITY OF MASSACHUSETTS, MASSACHUSETTS BIOLOGIC LABORATORIES, (“UMass” and “MBL” respectively) each of UMass and MBL with an address of 460 Walk Hill Street, Mattapan, Massachusetts, 02126, USA, , WORCESTER CITY CAMPUS CORPORATION, having its place of business at 55 Lake Avenue North, Worcester, MA 01655, (“WCCC”). Medarex and UMass are referred to hereinafter collectively as “Licensors”. Merck, UMass, MBL, WCCC and Medarex are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COMMERCIALIZATION AGREEMENT BETWEEN GILEAD SCIENCES LIMITED AND BRISTOL-MYERS SQUIBB COMPANY DATED AS OF DECEMBER 10, 2007Commercialization Agreement • February 27th, 2008 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This COMMERCIALIZATION AGREEMENT (this “Agreement”) dated and effective as of December 10, 2007 (the “Effective Date”) is hereby made by and between Gilead Sciences Limited, a limited company organized and existing under the laws of Ireland, having offices at Unit 13 Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland (“Gilead Sub”), and Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having offices at 345 Park Avenue, New York, New York 10154, USA (“BMS”) (each of Gilead Sub and BMS, a “Party” and, collectively, the “Parties”).
COMMERCIALIZATION AGREEMENTCommercialization Agreement • November 2nd, 2006 • Pharmacopeia Drug Discovery Inc • Services-commercial physical & biological research
This Amendment No. 1 (this “Amendment”), effective as of August 1, 2006 (the “Amendment Effective Date”), is entered into by and between SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a Pennsylvania corporation having a principal place of business at One Franklin Plaza, 200 N 16th Street, Philadelphia, PA 19102 (“SB Corp”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GGL”), SB Corp and GGL being collectively referred to hereinafter as “GSK”; and Pharmacopeia Drug Discovery, Inc., a Delaware corporation having a principal place of business at 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (“Pharmacopeia”). Pharmacopeia and GSK are each referred to herein by name or as a “Party” or, collectively, as the “Parties.” The Parties do hereby enter into this Amendment in order to amend that certain Product Development and C
Ex-US Commercialization AgreementCommercialization Agreement • May 2nd, 2018 • Foundation Medicine, Inc. • Services-medical laboratories • New York
WHEREAS, FMI has certain products that it currently commercializes, and additional products that it would like to commercialize in the future, either by itself or through a collaborator;
2013 Amendment to License, Development, Manufacturing and Commercialization AgreementCommercialization Agreement • February 11th, 2014 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This 2013 Amendment to the License, Development, Manufacturing and Commercialization Agreement (this “2013 Amendment”) is effective as of November 19, 2013 (the “Amendment Effective Date”) and is entered into by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with corporate offices at 130 Waverly Street, Cambridge, MA 02139-4242, United States of America (“Vertex”) and Janssen Pharmaceutica NV, a Belgium corporation with corporate offices at 30, Turnhoutsesteenweg, B-2340 Beerse, Belgium (“Janssen”).
